As the opening bell sounded and stocks got off to a sluggish start, I decided to take a look for stocks that got off to a fast start. One of those stocks is Botox-maker Allergan (AGN). In early trading, the pharmaceutical firm was more than a percentage point higher, so I took to digging to find out why.

The biggest news I found for Allergan was that it entered into an Amended and Restated License, Development and Marketing Agreement with Inspire Pharmaceuticals. The agreement deals with terms related to the Prolacria 2% development program and Inspire's right to receive revenues from Allergan relating to net sales of Restasis and any other human opthalmic formulations of cyclosporine owned or controlled by Allergan. Simply put, Inspire will receive revenues on net sales of Restasis and any related cyclosporine-based medicines.

Continue reading Allergan Rallies on News of License Agreement

Allergan Rallies on News of License Agreement originally appeared on BloggingStocks on Wed, 25 Aug 2010 10:30:00 EST. Please see our terms for use of feeds.

Continue reading Abbott Labs wishes upon a StarLIMS

Abbott Labs wishes upon a StarLIMS originally appeared on BloggingStocks on Tue, 15 Dec 2009 10:40:00 EST. Please see our terms for use of feeds.

Earlier this week I met with three CEOs of the neurotech industry -- Ron Cohen of Acorda Therapeutics (NASDAQ: ACOR), Uli Hacksell of Acadia Pharmaceuticals (NASDAQ: ACAD) and Jörn Aldag, of Evotec (NASDAQ: EVTC) -- along with Zack Lynch, the director of their trade association. Their November 10 media tour gave me a chance to gain some insight into this niche within the biotech industry of companies seeking cures for brain illnesses through drugs and devices.

At a time when revenues from blockbuster drugs are tapering off as their patents expire, these companies -- and their two-year-old Neurotechnology Industry Organization -- are hoping to unlock a new area of business growth while offering cures to ailments of longer-living populations and diseases involving the central nervous system.

Hawthorne, New York-based Acorda is already selling its first product, Zanaflex Capsules, which help control spasticity. Its Fampridine medication, aimed at bettering the walking capability of people with multiple sclerosis, is still undergoing Phase 3 testing. Update: November 14: Ron Cohen let me know Acorda has successfully completed Phase 3 testing of Fampridine
and intends to apply early next year for Food and Drug Administration approval to market it.

Meanwhile, San Diego-based Acadia, led by Hacksell, is conducting Phase 3 clinical trials of pimavanserin, which addresses psychosis related to Parkinson's disease.

Evotec, a Hamburg, Germany, company, whose acquisition of San Francisco-based Renovis in May could better position it to attract U.S. venture capital, is working on remedies for insomnia, Alzheimer's disease and smoking cessation.

Continue reading Can neurotech deliver on its growth promise? (ACOR, ACAD, EVTC)

Can neurotech deliver on its growth promise? (ACOR, ACAD, EVTC) originally appeared on BloggingStocks on Wed, 12 Nov 2008 13:35:00 EST. Please see our terms for use of feeds.

A graph from the May 2008 issue of Harvard Business Review tells a story about the dumbing down of the global economy.

From an article, Rebuilding the R&D Engine in Big Pharma [subscription required] the graph shows the total shareholder returns for various industries in two time periods: from 1985 to 2000 and from 2001 to 2007. Here are three of the leading sectors from 1985 to 2000 (average annual shareholder returns are in parentheses):

• Pharmaceuticals (20.0%)
• Financials (18.8%)
• IT (17.4%)

Between 2001 and 2007, three of the leading sectors were:

• Energy (15.2%)
• Materials (14.3%)
• Financials (7.0%)

Continue reading The dumbing down of the global economy

The dumbing down of the global economy originally appeared on BloggingStocks on Mon, 02 Jun 2008 17:34:00 EST. Please see our terms for use of feeds.

ZGEN: ZymoGenetics Inc. gaining insider action originally appeared on BloggingStocks on Mon, 28 Apr 2008 15:35:00 EST. Please see our terms for use of feeds.

Continue reading Gilead Sciences likes taking the lead in the sector

Gilead Sciences likes taking the lead in the sector originally appeared on BloggingStocks on Tue, 15 Apr 2008 18:07:00 EST. Please see our terms for use of feeds.

MAJOR PAPERS:

• Mining companies BHP Billiton Limited (NYSE: BHP) and Rio Tinto Plc (NYSE: RTP) are not only competing over iron-ore customers, but they are not competing for investors as well, according to the Wall Street Journal's "Heard on the Street." BHP says 60% of their investors also own Rio shares; Rio puts the figure at 50%.
• Prices for the top 50 branded drugs increased an average of 6.73% in 2006 and 7.82% last year at wholesale, according to market research firm Delta Marketing Dynamics. Often targeted by politicians, pharmaceutical companies are undeterred, the Wall Street Journal reported.

• According to iSuppli sources, Apple Inc (NASDAQ: AAPL) has cut its 2008 NAND order forecast and informed suppliers that its demand growth will slow in 2008 vs. 2007.
• The Boeing Company (NYSE: BA) is considering suspending work on the short-range version of its 787 jet, the -3 shorthaul, in an attempt to get production of the long-range version, the long-range -8, back on track, Flight Blogger said.

Newspaper wrap-up: Boeing may suspend production on short-range 787 originally appeared on BloggingStocks on Thu, 21 Feb 2008 08:00:00 EST. Please see our terms for use of feeds.

Continue reading Government diabetes study hits a speed bump

Government diabetes study hits a speed bump originally appeared on BloggingStocks on Thu, 07 Feb 2008 15:00:00 EST. Please see our terms for use of feeds.

Shares of Swiss pharmaceutical maker Novartis AG (NYSE: NVS) are lower in early morning trading after the company announced its fourth-quarter net profit fell by 45%, hurt by a restructuring charge and higher generic competition.

Novartis said net profit attributable to shareholders slipped to $904 million from $1.65 billion in the fourth quarter. Net profit from continuing operations also plunged 42% to $931 million from $1.6 billion in the same period of last year. The results were below analysts' average estimate of a profit of $1.33 billion. Included in the company's figures was a $444 million charge related to Novartis's cost-savings program pressured earnings.

However, Novartis results weren't really a surprise, as analysts had anticipated the fourth quarter would be weak for the drugmaker after the company announced in December that it would cut 2,500 jobs worldwide. Its decision came on worries over ongoing challenges from generics producers. Novartis declared that the job cuts brought the $444 million fourth-quarter charge, but it expects to save $1.6 billion in costs each year until 2010.

Continue reading Novartis (NVS) fourth-quarter profit plunges

Novartis (NVS) fourth-quarter profit plunges originally appeared on BloggingStocks on Thu, 17 Jan 2008 11:40:00 EST. Please see our terms for use of feeds.

Pfizer (NYSE: PFE) shares are slightly cheaper now than a decade ago, even though the company's per-share profits are more than 70% higher. The stock is unloved for a reason: Pfizer, like many drug makers at the moment, is finding it difficult to develop new medicines.

The company's biggest seller, Lipitor for lowering cholesterol, faces the loss of patent protection in 2011. Two of Pfizer's past hits, Zoloft for depression and Norvasc for high blood pressure, are already losing sales to generic competitors. Last year, a promising inhaled insulin flopped in the marketplace. The year before, a drug that raises levels of so-called good cholesterol proved too risky, and research was halted.

And Pfizer isn't alone. Last year, the Food and Drug Administration approved just 16 first-of-its-kind drugs, a 20-year low.

All that said, I think the stock warrants a purchase at today's price for five reasons.

Continue reading Five reasons to buy Pfizer (PFE)

Five reasons to buy Pfizer (PFE) originally appeared on BloggingStocks on Fri, 11 Jan 2008 16:31:00 EST. Please see our terms for use of feeds.

MAJOR PAPERS:

• The Wall Street Journal's "Heard on the Street" reported that analysts believe investors should take a look at some Indian pharmaceutical stocks, including two of the subcontinent's biggest generics makers, Dr. Reddy's Laboratories Limited (NYSE: RDY) and Cipla Ltd.
• According to the Wall Street Journal's "Heard in Asia," shares of India's three largest tech and outsourcing companies by sales, Infosys Technologies Limited (NASDAQ: INFY), Tata Consultancy Services and Wipro Limited (NYSE: WIT), may be worth a look by investors despite some near-term volatility.

• David Letterman is seeking his own deal with the Writers Guild of America which would allow his show to return to air on CBS Corporation's (NYSE: CBS) CBS station in early January even if the strike is continuing, the New York Times reported.
• According to the UK Times, Ford Motor Company (NYSE: F) is expected to name Tata as the preferred bidder for its Jaguar and Land Rover units.

Newspaper wrap-up: Time to take a look at Indian pharmaceuticals? originally appeared on BloggingStocks on Mon, 17 Dec 2007 08:00:00 EST. Please see our terms for use of feeds.

Pfizer (NYSE: PFE) is facing a number of lawsuits that say its painkiller Celebrex can cause heart attacks. Yesterday, a court threw some of those cases out. The Wall Street Journal wrote "U.S. District Judge Charles R. Breyer of San Francisco ruled that plaintiffs in the litigation haven't presented scientifically reliable evidence that Celebrex caused heart attacks or strokes when taken at a daily dosage of 200 milligrams." Pfizer says that the 200 milligram dose is the one most commonly given.

The cases involving Celebrex include over 3,000 plantiffs, and some are suing about effects of the drug at a higher dose, but the ruling is still a considerable relief for the big pharma company.

Like most drug liability cases, this one hinges on whether Pfizer knew that there were risks that the drug could cause significant problems beyond those disclosed on the labels. In that case, the amount of the dose would seem to be academic, especially for anyone who became sick.

But the court may have more wisdom than Wall Street and some plaintiffs will go unrewarded. As the tobacco companies proved two decades ago, suing big business rarely yields much reward.

Douglas A. McIntyre is an editor at 247wallst.com.

Pfizer spared from some Celebrex lawsuits originally appeared on BloggingStocks on Tue, 20 Nov 2007 08:20:00 EST. Please see our terms for use of feeds.

• Bernstein initiated global pharmaceutical stocks with a Cautious view. The firm initiated Merck & Co Inc (NYSE: MRK), Schering Plough Corporation (NYSE: SGP) and Wyeth (NYSE: WYE) with Outperform ratings, as well as Bristol-Myers Squibb Company (NYSE: BMY) and Eli Lilly & Company (NYSE: LLY) with Market Perform ratings.
  
• CIBC resumed coverage of Rigel Pharmaceuticals Inc (NASDAQ: RIGL) with a Sector Outperformer rating and $16 target. The firm expects near-term upside to be driven by positive phase 2 results of R788 in rheumatoid arthritis, expected in December, and thinks the company's strong scientific platform will support long-term appreciation.
  
• Bear Stearns started Brightpoint Incorporated (NASDAQ: CELL) with an Outperform rating and $20 target, as they are positive on Brightpoint's merger with Dangaard given the significant synergies and diversification it provides.

• Genitope Corporation (NASDAQ: GTOP) was initiated with a Neutral rating at Merriman.
  
• Grubb & Ellis Company (NYSE: GBE) was reinstated with an Outperform rating at William Blair.
  
• Roth Capital started Emcore Corporation (NASDAQ: EMKR) with a Buy rating and $13.80 target.
  
• Morgan Stanley started ING Groep NV (NYSE: ING) with an Equal Weight rating.

Analyst initiations: Pharmaceutical stocks, RIGL and CELL originally appeared on BloggingStocks on Wed, 24 Oct 2007 11:30:00 EST. Please see our terms for use of feeds.

In one of the worst moves by a large pharma company in recent memory, Pfizer Inc. (NYSE: PFE) is tying up with doctor social network Sermo. According to The Wall Street Journal, "Pfizer-affiliated doctors will be able to talk candidly with the site's 31,000 members, potentially giving the company insights into prescribing patterns and a way to show doctors data on its drugs."

The paper points out that there is some risk in the move because the FDA and other federal agencies watch drug company communications with doctors very carefully. But Pfizer has cut its sales force and the internet may be a way for the company to do some not so subtle marketing.

The part of the plan that is really flawed is that Sermo could become a platform for groups of doctors to mount powerful criticisms of Pfizer drugs or offer clinical evidence that pending or current drugs may represent unacceptable risks to patients. In other words, the social network could undo as many sales as it makes for the big drug company.

It is Pandora's Box that Pfizer will wish it has not opened.

Douglas A. McIntyre is a partner at 24/7 Wall St.

Pfizer (PFE) makes a MySpace move originally appeared on BloggingStocks on Mon, 15 Oct 2007 10:36:00 EST. Please see our terms for use of feeds.

UST (NYSE: UST) volatility Flat; UST down 6%; Altria Group (NYSE: MO) testing Marlboro Moist Smokeless tobacco. UST, a leading producer and marketer of moist smokeless tobacco products (Skoal, Copenhagen), is recently down $3.06 to $48.91. MO announced the introduction of Marlboro Moist Smokeless tobacco into test market. MO had been frequently mentioned as possibly interested in UST. UST has a market cap of $7.7 billion with quarterly March 2007 total revenue of $447 million. UST September option implied volatility of 26 is near its 26-week average of 23 according to Track Data, suggesting non-directional price risk.

Forest Labs (NYSE: FRX) volatility Elevated on patent challenge Appeal. FRX, a U.S. based pharmaceutical company, is recently down .48 to $37.74. FRX's Lexapro, an antidepressant accounting for 66% of FRX total revenue, is facing a patent challenge appeal.Buckingham Research says "LXP patent challenge appeal which we would expect to be resolved from an appellate decision over the next few months (we expect FRX to prevail in this case)." FRX call option volume of 9,195 contracts compares to put volume of 4,571 contracts. FRX September option implied volatility of 70 is above its 26-week average of 33 according to Track Data, suggesting larger price risks.

Daily options Update is provided by Stock Specialist Paul Foster of theflyonthewall.com.

Option update: UST has competition from Altria (MO) originally appeared on BloggingStocks on Tue, 21 Aug 2007 16:55:00 EST. Please see our terms for use of feeds.

DepoMed: Back to the drawing board on Gabapentin originally appeared on BloggingStocks on Tue, 10 Jul 2007 15:20:00 EST. Please see our terms for use of feeds.

MOST NOTEWORTHY:

• Medarex Inc (NASDAQ: MEDX) was initiated with a Positive rating at Susquehanna. The firm said Medarex has multiple drivers include a potential buyout by one of its existing partners, as well as clinical progress and the success of its technology platform in monoclonal antibody therapeutics.
• Susquehanna also initiated shares of Dyax Corporation (NASDAQ: DYAX), Millennium Pharmaceuticals Inc (NASDAQ: MLNM), and Idera Pharmaceuticals Inc (AMEX: IDP) with Neutral ratings and Dynavax Technologies Corporation (NASDAQ: DVAX) and Coley Pharmaceutical Group Inc (NASDAQ: COLY) with Positive ratings.
• Rayonier Inc (NYSE: RYN), Plum Creek Timber Company Inc (NYSE: PCL) and Weyerhaeuser Company (NYSE: WY) were initiated with Buy ratings at Merrill Lynch.
• Kona Grill was initiated with an Outperform rating at Cowen. The firm believes Kona can grow its asset base 10-fold at strong store-level cash-on-cash ROICs.

• Jefferies initiated shares of Input/Output Inc (NYSE: IO) with a Buy rating and $19 target.
• Goldman Sachs initiated shares of Minerals Technologies Inc (NYSE: MTX) with a Buy rating and $80 target.
• JP Morgan initiated shares of Orexigen Therapeutics Inc (NASDAQ: OREX) with an Overweight rating and is positive on the company's obesity pipeline.

Analyst initiations 6-07-07: Pharmaceutical companies, timber and KONA originally appeared on BloggingStocks on Thu, 07 Jun 2007 11:18:00 EST. Please see our terms for use of feeds.

Amgen and Pfizer: Down-and-out drug stocks to consider originally appeared on BloggingStocks on Mon, 21 May 2007 12:34:00 EST. Please see our terms for use of feeds.

MAJOR PAPERS:

• Time Warner Inc (NYSE: TWX) senior executives are considering reducing the company's cable-TV holdings over time, reported the Wall Street Journal.

• The $27B private equity buyout of Clear Channel Communications Inc (NYSE: CCU) is in greater jeopardy as the California Public Employees' Retirement System, or CalPERS, said yesterday that it plans to vote against the deal, reported the New York Post.
• According to diplomatic sources in Beijing, Iran and North Korea are working to "deepen cooperation" on the countries nuclear weapons technology, reported the Telegraph.
• India's Economic Times reported that Mid-sized Indian pharmaceutical companies including Orchid Chemicals, Strides Arcolab, Glenmark Pharma, Granules India, Shasun Chemicals and Plethico Pharmaceuticals are all looking for acquisitions in Russia, Europe and the United States.

• LightReading.com reported, citing a source close to the matter, that Sprint Nextel Corporation (NYSE: S) is considering a buyout of Vonage Holdings Corporation (NYSE: VG) and the two have been in talks to attempt to resolve Sprint's patent lawsuit against the VoIP provider.
• Rumors are swirling that "quality problems" may cause Apple Inc (NASDAQ: AAPL) to delay the launch of its upcoming iPhone, according to LoopRumors.com, citing Smarthouse News Australia.

Newspaper wrap-up 4-17-07: iPhone to be delayed? originally appeared on BloggingStocks on Tue, 17 Apr 2007 09:13:00 EST. Please see our terms for use of feeds.

There's a very interesting feature over at The Motley Fool and I find it very useful . The CAPS community stock rating pages give highly understandable insight plus gems of investor feedback which help to bring the knowledge about individual stocks to a layman's level. Investment players like me benefit from this feature.

La Jolla Pharmaceutical Company (NASDAQ:LJPC) has the CAPS number one spot this weekend based on a 43.1% stock value spike fueled by moderately positive interim results in a phase III study of its number one product Riquent. The drug in question shows promise in the treatment of Lupus, a chronic inflammatory disease that can cause organ malfunction. However, analysts are skeptical regarding the value of this phase III test result as a basis for developing a strong position in the company.

Even those investors who express a positive mood, unwittingly show reservations about whether or not the LJPC spike can be supported. Analyst consensus is "hold" on LJPC stock and neutral on the company. It is worthy of note that an Associated Press news release regarding the LJPC test results states: "Several drug makers are in advanced stage trials for lupus drugs. To date, no specific lupus drug has been approved in the United States."(emphasis mine)

I myself expect LJPC share value to recede quickly and I would base my choices on that belief. I see nothing else of interest in the company's fundamentals... at least not to the positive side. If I had shares of JLPC which I purchased at bargain, I'd be tempted to unload half of them immediately to reap some of the current gain. If I had bought those shares for a higher price, I'd be comfortable holding on to them for a while just to see what develops.

La Jolla Pharma: What are the Fools saying? originally appeared on BloggingStocks on Mon, 12 Mar 2007 14:30:00 EST. Please see our terms for use of feeds.